Linarin Reverses Doxorubicin Resistance by Modulating PTEN and MDR1 Expression in MCF-7 Breast Cancer Cells
Linarin may represent a promising adjunct therapeutic agent for overcoming resistance to conventional chemotherapeutic drugs, mediated through PTEN upregulation, which appears to play a role in suppressing P-gp-associated resistance mechanisms.